PMID: 6159320Jan 1, 1980Paper

Studies of two H-2Db mutants: B6. C-H-2bm13 and B6.C-H-2bm14

Immunogenetics
G M MorganD W Bailey

Abstract

Two new C57BL/6 H-2 mutants, B6.C-H-2bm13 and B6.C-H-2bm14 are described. They arose independently in C57BL/6 as spontaneous mutations of the gain and loss type. Complementation studies map the mutations in both bm13 and bm14 to the H-2Db gene. However, these two mutant strains are not identical, but occurred as independent mutations at the same locus, as shown by reciprocal graft rejection and by the inability of the (bm13 X bm14)F1 hybrid to accept C57BL/6 grafts. Serological studies by direct testing (cytotoxicity and hemagglutination) and by quantitative absorption demonstrated a decrease in the H-2Db private specificity H-2.2 in both bm13 and bm14 when compared to C57BL/6. This was confirmed by SDS-PAGE analysis using antisera detecting the H-2.2 specificity. Attempts to produce antibodies to either the gained or lost specificities of the two mutant strains failed.

References

Dec 1, 1979·The Journal of Experimental Medicine·I F McKenzieH I Kohn
Jan 1, 1978·Advances in Immunology·J Klein
Jan 1, 1978·Journal of Immunological Methods·C R Parish, I F McKenzie
Mar 1, 1975·Mutation Research·H I Melvold RW Kohn
Jul 1, 1980·Immunogenetics·I F McKenzieR W Melvold
Dec 1, 1978·Immunogenetics·H I KohnD C Shreffler

❮ Previous
Next ❯

Citations

May 1, 1982·European Journal of Immunology·P M HogarthI F McKenzie
Jan 1, 1987·Immunogenetics·J P DaleyI Nakamura
Jan 1, 1983·Immunogenetics·A R TownsendB A Askonas
Jan 1, 1983·Immunogenetics·J Michaelson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.